

HIGHLIGHT ARTICLE

Pharmacogenetics and Other Molecular Targets in the Management of Pancreatic Adenocarcinoma

Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010

Eirini Merika¹, Konstantinos N Syrigos², Muhammad Wasif Saif³

¹West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College London. London, United Kingdom.

²Oncology Unit, Third Department of Medicine, Athens Medical School. Athens, Greece.

³Section of Medical Oncology, Yale University School of Medicine. New Haven, CT, USA

Summary

Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management through identification of molecular targets and prognostic factors to overcome the limits of efficacious chemotherapy delivery.

What We Knew before ASCO 2010

Pancreatic cancer remains the most lethal, aggressive abdominal malignancy, frequently presenting at the metastatic stage. This renders treatment extremely difficult, leading to poor prognosis and five-year survival of 15% for early stage disease and life expectancy of 6-11 months for locally advanced disease [1]. The main challenges in the treatment of locally advanced pancreatic adenocarcinoma are understanding pancreatic tumour behaviour and microenvironment, overcoming the limits of delivery and efficacy of chemotherapy and identifying biomarkers for prediction of outcome success.

What We Learnt at ASCO 2010

Pancreatic Microenvironment

It is well recognised that the pervasive growth of dense, collagen-rich, fibrous tissue around pancreatic tumours, known as the desmoplastic reaction, forms a barrier to chemotherapy penetration and hence efficacy.

Key words BRAF protein, human; epidermal growth factor receptor-neu receptor; KRAS protein, human; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide

Abbreviations ASCO: American Society of Clinical Oncology; MMP: matrix metalloproteinase; MT1-MMP: membrane type 1-matrix metalloproteinase

Correspondence Muhammad Wasif Saif
Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT, USA
Phone: +1-203.737.1569; Fax: +1-203.785.3788
E-mail: wasif.saif@yale.edu

Document URL <http://www.joplink.net/prev/201007/25.html>

Many matrix metalloproteinases (MMPs) have been associated with the extent of the desmoplastic reaction as well as enhanced adhesion and invasion of pancreatic tumours [2, 3]. Protein membrane type 1-matrix metalloproteinase (MT1-MMP) is over-expressed in colorectal [4] and lung tumour cells [5] and serves as a key protein for tumour growth and invasiveness. MT1-MMP appears to activate MMP-2, which has a catalytic function in the basement membrane degradation (Figure 1), leading to increased




Figure 1. Matrix degradation by MT1-MMP (with permission of Yoshifumi Itoh Lab Imperial College. London, UK).

pancreatic cancer cell invasiveness but their expression is also directly linked with the extent of the desmoplastic reaction in pancreatic cancer tissue [6]. New evidence in the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting shows that these MMPs may also be implicated in the tumour microenvironment and pose an obstacle to treatment penetration to the tumour. Krantz *et al* (Abstract #4158) demonstrated that MT1-MMP over-expression in transgenic mice led to an increase not only of pre-cancerous lesions and metaplasia but also in tumour invasiveness [7]. They also showed that MT1-MMP is linked to more peripancreatic tumour fibrosis. This study comes to support our knowledge of the role of MMPs in tumour progression and the desmoplastic reaction. MMPs seem to play multiple roles in tumour progression and further investigation has the potential of serving as a molecular target for treatment delivery.

Molecular Targets and Pancreatic Cancer

One of the most interesting studies presented at ASCO Annual Meeting in relation to pancreatic cancer, showed an association between certain *KRAS* mutations and reduction in overall survival in pancreatic cancer patients after surgery. Recent research, as seen in the CRYSTAL [8], OPUS [9] and CAIRO 2 [10] trials, suggests that genetic polymorphisms can be used to predict treatment outcome, such as *KRAS* and *BRAF* mutations in colorectal cancer and response to monoclonal antibodies against EGFR, such as cetuximab or panitumumab. Certain mutations in particular serve as negative predictive factors for therapy success, as expressed in the provisional clinical opinion in the ASCO 2009 Gastrointestinal Meeting [11]. The *KRAS/BRAF* pathway has also been shown to play a key role in the development of pancreatic ductal adenocarcinoma [12].




Figure 2. XPD protein (with permission of Department of Energy Lawrence Berkeley National Laboratory, CA, USA).

The investigators from Denmark looked at the presence of *KRAS*, *BRAF* and *HER2* mutations in patients operated for pancreatic adenocarcinoma and their link to overall survival (Abstract #4043 [13]). Certain variations in the *KRAS* genotype could be correlated with a poorer overall survival (hazard ratio, HR: 1.48; 95% CI: 1.07-2.05; P=0.02). In fact the HR for overall survival was 1.79 in patients who had certain *KRAS* mutations compared to patients with normal variations of *KRAS*. The majority of mutations occurred in codons 12 and 13, as in colorectal cancer patients.

Whether this gene analysis will lead to better future treatment outcomes by targeting EGFR in the subgroup of patients with these mutations remains to be seen. Analysis of a single gene is unlikely to be fully informative of the exact pharmacogenetic mechanism. However, the results suggest it is worth pursuing the route of analysis and genotyping of specific oncogenes present in pancreatic cancer patients, which can subsequently serve as molecular targets for successful treatment. Needless to say this will be true for other cancers, such as breast and gastric. The *KRAS/BRAF* pathway has potential to serve as predictive factor for anti-EGFR therapy in various gastrointestinal tumours.

Pharmacogenetics

Two papers look into the prognostic significance between gene polymorphisms and treatment success. One of the main challenges in the treatment of pancreatic cancer patients is overcoming resistance to chemotherapeutic agents. Traditional and even newer pharmaceutical therapeutic regimens are limited in terms of tolerance, efficacy and cross-resistance. Resistance is multifaceted and stems from both tumour immunosuppressive mechanisms as well as genetic polymorphisms.

Various genes have been characterised that contribute to tumour cell protection against immune defence mechanisms, such as the *xCT* gene, which codes for part of the plasma membrane cysteine/glutamate transporter [14]. This balance is critical for protection of tumour cells against the immune system [15].

In the first paper Huang *et al.* (Abstract #4065 [16]), looked at the prognostic significance of single nucleotide polymorphisms in the *xCT* gene in patients with advance pancreatic cancer treated with gemcitabine and platinum. They identified specific polymorphisms that correlated with better overall survival in patients receiving treatment, with maximum median survival time of 13.6 months for specific genotypes alone and even higher at 14.1 months in patients receiving the combination treatment.

In the second paper Pacetti *et al* (Abstract #4098 [17]) exploited polymorphisms in genes involved in activity and resistance to drugs, mainly DNA repair gene polymorphisms, in an effort to link them to treatment response. The substitution of Gln for Lys in position 751 of the *XPD* gene (Figure 2) led to increased overall survival from 262 days (95% CI: 202-423 days) to 446 (95% CI: 346-446 days).

Both papers suggest that genetic variants in genes like *xCT* have the potential to serve as predictors of treatment outcome and to the development of personalised chemotherapeutic therapy.

Conclusion

The 2010 ASCO Annual Meeting in relation to pancreatic cancer focuses towards the emerging field of identification of molecular biomarkers and molecular profiling in treatment selection and highlights the challenges this emerging field presents. These advances in genomic, transcriptomic and proteomic technologies have led to a step towards materialisation of the concept of personalised medicine. There is still a significant gap between literature and routine clinical practice, which needs to start bridging.

Conflict of interest The authors have no potential conflicts of interest

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. *CA Cancer J Clin* 2008; 58:71-96. [PMID 18287387]
2. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. *Int J Cancer* 2000; 85:14-20. [PMID 10585576]
3. Määttä M, Soini Y, Liakka A, Autio-Harjainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. *Clin Cancer Res* 2000; 6:2726-34. [PMID 10914717]
4. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of colon, breast, and head and neck carcinomas. *Proc Natl Acad Sci U S A* 1995; 92:2730-4. [PMID 7708715]
5. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. *Nature* 1994; 370:61-5. [PMID 8015608]
6. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. *J Natl Cancer Inst* 1993; 85:574-8. [PMID 8384265]
7. Krantz SB, Dangi-Garimella S, Shields MA, Grippo PJ, Bentrem HG, Munshi HG. Role of MT1-MMP and Kras in invasive pancreatic tumors with pronounced fibrosis. *J Clin Oncol* 2010; 28(15 Suppl):4158.
8. E. Van Cutsem, I. Lang, G. D'Haens, V. Moiseyenko, J. Zaluski, G. Folprecht, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. *J Clin Oncol* 2008; 26(15 Suppl):2.
9. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. *J Clin Oncol* 2008; 26(15 Suppl):4000.
10. Punt CJ, Tol J, C. Rodenburg CJ, Cats A, Creemers G, Schrama JG, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). *J Clin Oncol* 2008; 26(15 Suppl):LBA4011.
11. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol* 2009; 27:2091-6. [PMID 19188670]
12. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. *Best Pract Res Clin Gastroenterol* 2006; 20:211-26. [PMID 16549325]
13. Schultz NA, Roslind A, Heeran M, Christensen IJ, Hogdall EV, Horn T, et al. KRAS, BRAF mutations, and HER2 expression in patients operated for pancreatic adenocarcinomas. *J Clin Oncol* 2010; 28(15 Suppl):4043.
14. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. *J Cell Physiol* 2008; 215:593-602. [PMID 18181196]
15. Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. *Br J Cancer* 2008; 99:464-72. [PMID 18648370]
16. Huang TJ, Li D, Weatherly J, Tang H, Gout PW, Wolff RA, et al. Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLTA). *J Clin Oncol* 2010; 28(15 Suppl):4065.
17. Pacetti P, Giovannetti E, Reni M, Mambrini A, Ghidini M, Gleon L, et al. Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. *J Clin Oncol* 2010; 28(15 Suppl):4098.